ArticleFrontiers in endocrinology2025
Accuracy of a novel calibratable real-time continuous glucose monitoring device based on FreeStyle libre in- and out-of-hospital.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Based on FreeStyle Libre, we designed QT AIR, an advanced real-time, calibrated Continuous Glucose Monitoring (CGM) device. This study aim to validate the consistency and clinical accuracy of the product by comparing the capillary blood glucose (CBG) with CGM data in both in-hospital and outpatient scenarios. Methods: Results of CGM devices were compared with random capillary glucose values from users in both in-hospital and outpatient settings. The accuracy of CGMs was assessed through consistency analysis, Bland-Altman analysis, calculation of MARD and MAD, Consensus Error Grids, as well as analysis using the Continuous Glucose Deviation Interval and Variability Analysis (CG-DIVA). Results: In outpatient setting, 1907 values from 138 users were analyzed. FreeStyle Libre data, QT AIR calibrated and uncalibrated data showed strong positive correlations with capillary blood glucose values. The MARD values for the FreeStyle Libre, uncalibrated QT AIR, and calibrated QT AIR groups were 18.33%, 20.63%, and 12.39%, respectively. Consensus Error Grid, reference values in Zone A: FreeStyle Libre: 69.75%, QT AIR uncalibrated: 67.80%, QT AIR calibrated: 87.62%. The Bland-Altman analysis results suggest that FreeStyle Libre exhibitsed a systematic underestimation of blood glucose levels, while QT AIR almost rectified the differences. In the in-Hospital setting, the MARD of QT AIR after calibration was reduced to 7.24%. The Consensus error grid analyses of the in-Hospital data revealed that 95% of the calibrated QT AIR values fell within Zone A, a significantly higher proportion than that of other two group. The CG-DIVA analysis of the calibrated QT AIR device showed a median bias of -0.49% and a between-sensor variability of 26.65%, both of which are significantly lower than the corresponding values observed for the FreeStyle Libre device. Conclusions: We successfully transformed a retrospective CGM system into a real-time monitoring device. The monitoring accuracy of the device could be improved by calibration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.